Ascend Advanced Therapies

Ascend Advanced Therapies Contract Manufacturing & Development (CDMO) Profile

Ascend Advanced Therapies (Ascend) is a specialist adeno-associated

virus (AAV) development partner. In-house Gene to GMP capabilities span

from early research, including capsid development and vector optimization,

to full scale chemistry, manufacturing, and controls (CMC) solutions and

comprehensive regulatory guidance and support.

Ascend hit the ground running in 2023 with operational facilities

staffed with industry experts across the United States and Europe.

Working with the Ascend team guarantees a partner with unparalleled

insight and collaboration when delivering products from the bench through

to commercialization. A flexible platform has been thoughtfully built to

support all AAV serotypes across scales with proprietary and partnered

technologies including a world-class analytical toolkit.

GMP manufacturing capacity was added in 2024 via the acquisition of Beacon Therapeutics,

enabling the team to Aim Higher in balancing yield and quality of

commercially accessible life-saving therapies.

CDMO Services:
Cell & Gene Therapy Liquids Analytical Development; Cell Line Development; Drug Delivery System; Formulation Development; ICH Stability Testing; Process Development Viral Vector Vaccines

Number of Facilities: 1-2

Facility locations: Europe; North America

Website: Visit the Ascend Advanced Therapies website

Linkedin: Connect on Linkedin

Current Capacity: Capacity available upon request, based on availability across multiple sites. Non-GMP manufacturing available on a case-by case basis, GMP manufacturing available in early 2025.